✦ LIBER ✦

Combined use of orgaran and reopro during coronary angioplasty in patients unable to receive heparin

✍ Scribed by Warren J. Cantor; Kori Leblanc; Bernadette Garvey; K. Randal Watson; Al Rasymas; Bradley H. Strauss

Publisher: John Wiley and Sons
Year: 1999
Tongue: English
Weight: 31 KB
Volume: 46
Category: Article
ISSN: 1522-1946
DOI: 10.1002/(sici)1522-726x(199903)46:3<352::aid-ccd21>3.0.co;2-7

No coin nor oath required. For personal study only.

✦ Synopsis

Orgaran, a heparinoid, has been used successfully in patients with heparin-induced thrombocytopenia. We report three cases in which Orgaran was combined with the glycoprotein IIb/IIa receptor antagonist Reopro during coronary angioplasty. Orgaran was given as a single intravenous bolus of 1500 anti-factor Xa units. No ischemic or hemorrhagic complications occurred during or following the procedure. Cathet. Cardiovasc. Intervent. 46:352-355, 1999 Wiley-Liss, Inc.